AbbVie Inc. and Viatris Inc.: SG&A Spending Patterns Compared

SG&A Spending Trends: AbbVie Inc. vs. Viatris Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. AbbVie Inc. and Viatris Inc. have shown distinct patterns in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, AbbVie Inc. consistently outspent Viatris Inc., with a notable increase of approximately 66% in SG&A expenses, peaking in 2022. In contrast, Viatris Inc. demonstrated a more conservative approach, with a 210% increase over the same period, reflecting strategic investments post-2019. This divergence highlights AbbVie's aggressive market expansion and Viatris's steady growth strategy. As the pharmaceutical sector continues to face challenges and opportunities, these spending patterns offer insights into each company's priorities and future directions. Investors and industry analysts should watch these trends closely to gauge potential impacts on market positioning and shareholder value.